JP4680519B2 - Method for producing imidazole carbene metal complex - Google Patents
Method for producing imidazole carbene metal complex Download PDFInfo
- Publication number
- JP4680519B2 JP4680519B2 JP2004049441A JP2004049441A JP4680519B2 JP 4680519 B2 JP4680519 B2 JP 4680519B2 JP 2004049441 A JP2004049441 A JP 2004049441A JP 2004049441 A JP2004049441 A JP 2004049441A JP 4680519 B2 JP4680519 B2 JP 4680519B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- groups
- monovalent
- trivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
塩基等を用いない温和な条件下で製造することができ、再現性に優れ、且つ錯体形成の
対象となる金属の多いイミダゾールカルベン遷移金属錯体の製造方法に関する。
The present invention relates to a method for producing an imidazole carbene transition metal complex which can be produced under mild conditions without using a base and the like, is excellent in reproducibility, and contains a large amount of metal as a complex formation target.
カルベンが配位した金属錯体の製造例は、古くは1968年のWanzlickやOfeleらの研究に
端を発し、1970年代から80年代にかけてのLappertらの研究により多くの報告が行われて
きた。1991年にArduengoらによりカルベンそのものが単離・同定されて以来、さらに活発
な研究が展開されるようになった。これらのカルベンは炭素上にローンペア電子を有する
一重項カルベンであることから、3価リン化合物であるホスフィン類と同様に扱うことが
でき、ホスフィン類の代わりの支持配位子として用いた金属錯体に関する研究が展開され
るようになった。ホスフィン錯体と比べカルベンを用いた金属錯体は、反応活性の向上が
期待できるなど、多くの利点が明らかになってきた。
The production examples of metal complexes coordinated with carbene originated in the work of Wanzlick and Ofele et al. In 1968, and many reports have been made by Lappert et al. In the 1970s and 1980s. Since the carbene itself was isolated and identified by Arduengo et al. In 1991, more active research has been developed. Since these carbenes are singlet carbenes having a loan pair electron on carbon, they can be treated in the same way as phosphines that are trivalent phosphorus compounds, and metal complexes used as supporting ligands instead of phosphines. Research has started. Compared to phosphine complexes, metal complexes using carbene have revealed many advantages, such as an improvement in reaction activity.
これらのカルベンは、二価の炭素化学種でありながら単離可能であることからArduengo
らにより『安定カルベン』と命名されたが、その名に反して、酸素や水との反応性の高さ
から取り扱いには困難を極める。そのためカルベン錯体の製造において前駆体である塩を
適当な塩基で処理することにより、反応系中でカルベンを発生させ、そのまま金属錯体製
造へと適応する製造法が開発されてきた。しかし、時には、カルベンを発生させるための
塩基が、金属錯体前駆体と反応し、目的とする金属錯体が得られないという適応範囲が限
られた製造法であることも、次第に明らかになってきた。
These carbenes are divalent carbon species but can be isolated, so Arduengo
Although it was named “Stable Carbene”, it was extremely difficult to handle because of its high reactivity with oxygen and water. Therefore, a production method has been developed in which a carbene is generated in a reaction system by treating a salt, which is a precursor in the production of a carbene complex, with a suitable base, and is directly applied to the production of a metal complex. However, it has gradually become clear that the base for generating carbene reacts with the metal complex precursor and the desired metal complex cannot be obtained. .
この問題を解決するためのカルベン金属錯体の製造法は、ホスフィン錯体の製造がそう
であるように、カルベンをそのまま錯体製造に用いることである。そのため、古くからカ
ルベン配位子の等価体となりうる化合物に関しての研究が展開されてきた。Lappertらは
電子リッチオレフィンと呼ばれるenetramine化合物からの二重結合の開裂によるカルベン
錯体製造を報告している。しかし、この方法におけるカルベン錯体製造においては、炭素
−炭素間の二重結合を開裂させてカルベンを発生させるために、高温条件が必要であるた
め、出発錯体あるいは目的錯体が分解を引き起こすことがあった。
A method for producing a carbene metal complex to solve this problem is to use the carbene as it is for the production of a complex, as in the production of a phosphine complex. Therefore, research on compounds that can be equivalent to carbene ligands has long been developed. Lappert et al. Have reported the production of carbene complexes by cleavage of double bonds from enetramine compounds called electron-rich olefins. However, in the carbene complex production in this method, since a high temperature condition is required to generate a carbene by cleaving a carbon-carbon double bond, the starting complex or the target complex may cause decomposition. It was.
このような背景から温和な条件下で塩基を使用することなくカルベンを容易に発生させ
ることのできる安定カルベンの等価体に関する研究が展開されている。Grubbsらは、イミ
ダゾリニウム塩から誘導されるアルコール付加体やクロロホルム付加体を用いて、カルベ
ン錯体へと導く方法を報告している。これらの付加体は、温和な条件でカルベン種を発生
させることが可能であり、カルベン等価体としての有用性が報告されている。
In view of this background, research has been conducted on stable carbene equivalents that can easily generate carbene without using a base under mild conditions. Grubbs et al. Have reported a method for converting to an carbene complex using an alcohol adduct or chloroform adduct derived from an imidazolinium salt. These adducts can generate carbene species under mild conditions, and their usefulness as carbene equivalents have been reported.
しかし、イミダゾリウム塩から誘導されるイミダゾール‐2‐イリデンに関しては、Wan
gとLinによって報告された酸化銀を用いた銀−カルベン錯体からのカルベントランスファ
ーによるカルベン錯体製造が報告されているだけである。
However, for imidazol-2-ylidene derived from imidazolium salts, Wan
Only carbene complex production by carbene transfer from silver-carbene complexes using silver oxide reported by g and Lin has been reported.
上記のようにカルベン金属錯体を製造する際にはイミダゾリウム塩を適当な塩基で処理
する必要があり、塩基を必要としないものでもenetramine化合物における炭素‐炭素間の
二重結合を開裂させてカルベンを発生させるために高温を必要としていた。
When preparing a carbene metal complex as described above, it is necessary to treat the imidazolium salt with an appropriate base, and even those that do not require a base can cleave the carbon-carbon double bond in the enetramine compound to cleave the carbene. It required high temperature to generate.
そこで本発明では塩基等を用いない温和な条件下でイミダゾールカルベン金属錯体を与
える製造方法を提供することを目的とする。
Therefore, an object of the present invention is to provide a production method for giving an imidazole carbene metal complex under mild conditions without using a base or the like.
本発明の一般式(3)で示されるイミダゾールカルベン金属錯体の製造方法は、一般式
(1)で示されるイミダゾールカルベン付加体と一般式(2)で示される金属錯体とを用
いることを特徴とするものである。
The method for producing an imidazole carbene metal complex represented by the general formula (3) of the present invention is characterized by using an imidazole carbene adduct represented by the general formula (1) and a metal complex represented by the general formula (2). To do.
[式中、nは、1から3の整数であり、R1は1から50個の炭素原子を有する1価から3価のアルキル基、1から50個の炭素原子を有する1価から3価のアルケニル基、1から50個の炭素原子を有する1価から3価のアルキニル基、および1から30個の炭素原子を有する1価から3価のアリール基よりなる群から選択され、これらの置換基は環式、非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換されていてもよい。
R2は1から50個の炭素原子を有するアルキル基、1から50個の炭素原子を有する
アルケニル基、1から50個の炭素原子を有するアルキニル基、および1から30個の炭
素原子を有するアリール基よりなる群から選択され、これらの置換基は環式、非環式、直
鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換され
ていてもよい。
R3およびR4は、同一または異なり、それぞれ水素、ハロゲン、ニトロ基、ニトロソ基
、アルコキシル基、アリールオキシ基、アミド基、カルボキシル基、カルボニル基、チオ
基、スルホニル基、1から50個の炭素原子を有するアルキル基、1から50個の炭素原
子を有するアルケニル基、1から50個の炭素原子を有するアルキニル基、および1から
30個の炭素原子を有するアリール基よりなる群から選択され、これらの置換基は環式、
非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基
で交換されていてもよい。
Eは、B、Al等の13族の元素であり、R5 は、炭素数1から20個のアルキル基、
アリール基、アルコキシル基からなる群から選択され、さらにこれらのうち少なくとも1
つの水素はアルコキシル基に置換されていてもよく、n’は1から4の整数である。]
[In the formula, n is an integer of 1 to 3, and R 1 is a monovalent to trivalent alkyl group having 1 to 50 carbon atoms, and a monovalent to trivalent group having 1 to 50 carbon atoms. Selected from the group consisting of alkenyl groups, monovalent to trivalent alkynyl groups having 1 to 50 carbon atoms, and monovalent to trivalent aryl groups having 1 to 30 carbon atoms. Groups may include cyclic, acyclic, straight chain and / or branched groups, and at least one hydrogen may be exchanged with a functional group.
R 2 is an alkyl group having 1 to 50 carbon atoms, an alkenyl group having 1 to 50 carbon atoms, an alkynyl group having 1 to 50 carbon atoms, and an aryl having 1 to 30 carbon atoms Selected from the group consisting of groups, these substituents may include cyclic, acyclic, linear and / or branched groups and at least one hydrogen may be replaced with a functional group .
R 3 and R 4 are the same or different and are each hydrogen, halogen, nitro group, nitroso group, alkoxyl group, aryloxy group, amide group, carboxyl group, carbonyl group, thio group, sulfonyl group, 1 to 50 carbons Selected from the group consisting of alkyl groups having atoms, alkenyl groups having 1 to 50 carbon atoms, alkynyl groups having 1 to 50 carbon atoms, and aryl groups having 1 to 30 carbon atoms, and The substituent of is cyclic,
Acyclic, straight chain and / or branched groups may be included and at least one hydrogen may be exchanged with a functional group.
E is a group 13 element such as B or Al, R 5 is an alkyl group having 1 to 20 carbon atoms,
Selected from the group consisting of aryl and alkoxyl groups, and at least one of these
One hydrogen may be substituted with an alkoxyl group, and n ′ is an integer of 1 to 4. ]
[式中、Mは6から10族の遷移金属元素で、低原子価(0から3価)の遷移金属元素であり、Lは中心金属に配位した単座または多座の荷電または荷電していない複数個の配位子である。] [Wherein M is a transition metal element of group 6 to 10 and is a low valence (0 to 3) transition metal element, and L is a monodentate or multidentate charged or charged coordinated to the central metal. There are no multiple ligands. ]
[式中、nは、1から3の整数であり、R1は1から50個の炭素原子を有する1価から3価のアルキル基、1から50個の炭素原子を有する1価から3価のアルケニル基、1から50個の炭素原子を有する1価から3価のアルキニル基、および1から30個の炭素原子を有する1価から3価のアリール基よりなる群から選択され、これらの置換基は環式、非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換されていてもよい。
R2は1から50個の炭素原子を有するアルキル基、1から50個の炭素原子を有するアルケニル基、1から50個の炭素原子を有するアルキニル基、および1から30個の炭素原子を有するアリール基よりなる群から選択され、これらの置換基は環式、非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換されていてもよい。
R3およびR4は、同一または異なり、それぞれ水素、ハロゲン、ニトロ基、ニトロソ基、アルコキシル基、アリールオキシ基、アミド基、カルボキシル基、カルボニル基、チオ基、スルホニル基、1から50個の炭素原子を有するアルキル基、1から50個の炭素原子を有するアルケニル基、1から50個の炭素原子を有するアルキニル基、および1から30個の炭素原子を有するアリール基よりなる群から選択され、これらの置換基は環式、非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換されていてもよい。
Mは6から10族の遷移金属元素で、低原子価(0から3価)の遷移金属元素であり、Lは中心金属に配位した単座または多座の荷電または荷電していない複数個の配位子である。]
一般式(1)および一般式(3)における官能基としては、ハロゲン、ニトロ基、ニトロソ基、アルコキシル基、アリールオキシ基、アミド基、カルボキシル基、カルボニル基、チオ基、スルホニル基があげられる。
[In the formula, n is an integer of 1 to 3, and R 1 is a monovalent to trivalent alkyl group having 1 to 50 carbon atoms, and a monovalent to trivalent group having 1 to 50 carbon atoms. Selected from the group consisting of alkenyl groups, monovalent to trivalent alkynyl groups having 1 to 50 carbon atoms, and monovalent to trivalent aryl groups having 1 to 30 carbon atoms. Groups may include cyclic, acyclic, straight chain and / or branched groups, and at least one hydrogen may be exchanged with a functional group.
R 2 is an alkyl group having 1 to 50 carbon atoms, an alkenyl group having 1 to 50 carbon atoms, an alkynyl group having 1 to 50 carbon atoms, and an aryl having 1 to 30 carbon atoms Selected from the group consisting of groups, these substituents may include cyclic, acyclic, linear and / or branched groups and at least one hydrogen may be replaced with a functional group .
R 3 and R 4 are the same or different and are each hydrogen, halogen, nitro group, nitroso group, alkoxyl group, aryloxy group, amide group, carboxyl group, carbonyl group, thio group, sulfonyl group, 1 to 50 carbons Selected from the group consisting of alkyl groups having atoms, alkenyl groups having 1 to 50 carbon atoms, alkynyl groups having 1 to 50 carbon atoms, and aryl groups having 1 to 30 carbon atoms, and The substituents may include cyclic, acyclic, straight chain and / or branched groups, and at least one hydrogen may be replaced with a functional group.
M is a transition metal element of group 6 to 10 and is a low valence (0 to 3 valence) transition metal element, and L is a monodentate or multidentate charged or uncharged plural coordinated to the central metal. It is a ligand. ]
Examples of the functional group in the general formula (1) and the general formula (3) include halogen, nitro group, nitroso group, alkoxyl group, aryloxy group, amide group, carboxyl group, carbonyl group, thio group, and sulfonyl group.
本発明によれば、塩基等を用いない温和な条件下でイミダゾールカルベン遷移金属錯体
を製造できる。
According to the present invention, an imidazole carbene transition metal complex can be produced under mild conditions without using a base or the like.
以下、本発明について、実施例を用いてさらに詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to examples.
実験はすべてアルゴン雰囲気下あるいは真空条件下で行った。すべてのイミダゾリウム
カルベン付加体は反応直前に約30分間真空下に放置したものを使用した。THF、トルエン
はナトリウムベンゾフェノンを用いて乾燥した。その他の溶媒は適切な乾燥剤を用いて蒸
留したものを使用した。その他、用いた試薬は市販品を入手しそのまま用いた。
All experiments were performed under an argon atmosphere or under vacuum conditions. All imidazolium carbene adducts were used under vacuum for about 30 minutes immediately before the reaction. THF and toluene were dried using sodium benzophenone. Other solvents were distilled using an appropriate desiccant. In addition, a commercially available product was obtained and used as it was.
[実施例1]
Mo(CO)5(iPr-imidazol carbene)錯体の合成
[Example 1]
Synthesis of Mo (CO) 5 ( i Pr-imidazole carbene) complex
シュレンクフラスコにiPr-imidazol carbene・BEt3を93 mg (0.37 mmol)とMo(CO)6を98
mg (0.37 mmol)を計り取り、シリンジを用いてトルエン10 mlを加えた。その後、リー
ビッヒ冷却管を取り付け、加熱還流を2時間行った。溶液の色は淡黄色から茶色みを帯び
た黄色に変化した。室温まで放冷した後、減圧下で溶媒を留去し、ヘキサンで洗浄後、真
空乾燥することにより、目的錯体を薄茶色固体として得た。収量112 mg (0.29 mmol, 収率78%)。
In a Schlenk flask, 93 mg (0.37 mmol) of i Pr-imidazole carbene-BEt 3 and 98 mg of Mo (CO) 6
mg (0.37 mmol) was weighed and 10 ml of toluene was added using a syringe. Thereafter, a Liebig condenser was attached and heated to reflux for 2 hours. The color of the solution changed from pale yellow to brownish yellow. After allowing to cool to room temperature, the solvent was distilled off under reduced pressure, washed with hexane, and then vacuum dried to obtain the target complex as a light brown solid. Yield 112 mg (0.29 mmol, 78% yield).
1H NMR(in CDCl3) δ 1.44(d,J=6.8Hz,12H,iPr−CH3),5.19(sept,J=6.8Hz,2H,iPr−CH),7.04(s,2H,CH=CH). 13C{1H}NMR(in C6D6) δ 23.5(iPr−CH3),53.3(iPr−CH),118.0(CH=CH),184.0(br,NCN),206.6(cis−CO),212.1(trans−CO). IR(KBr): νCO;1971,1925,1909,1888cm−1. Anal. Calcd for C14H16MoN2O5. C:43.31,H:4.15,N:7.22. Found. C:43.39,H:4.40,N:7.28. 1 H NMR (in CDCl 3 ) δ 1.44 (d, J = 6.8 Hz, 12H, i Pr—CH 3 ), 5.19 (sept, J = 6.8 Hz, 2H, i Pr—CH), 7.04 (s, 2H, CH = CH). 13 C { 1 H} NMR (in C 6 D 6 ) δ 23.5 ( i Pr—CH 3 ), 53.3 ( i Pr—CH), 118.0 (CH═CH), 184.0 (br) , NCN), 206.6 (cis-CO), 212.1 (trans-CO). IR (KBr): νCO; 1971, 1925, 1909, 1888 cm −1 . Anal. Calcd for C 14 H 16 MoN 2 O 5. C: 43.31, H: 4.15, N: 7.22. Found. C: 43.39, H: 4.40, N: 7.28.
上記により、Mo(CO)5(iPr-imidazol carbene)錯体の構造決定を行った。 From the above, the structure of the Mo (CO) 5 ( i Pr-imidazole carbene) complex was determined.
[実施例2]
Mo(CO)5(Mes-imidazol carbene)錯体の合成
[Example 2]
Synthesis of Mo (CO) 5 (Mes-imidazole carbene) complex
シュレンクフラスコにMes-imidazol carbene・BEt3を220 mg (0.55 mmol)とMo(CO)6を1
42 mg (0.54 mmol)計り取り、トルエンを15 ml加えた。混合物を3時間加熱還流した。そ
の後、Mo(CO)5(iPr-imidazol carbene)錯体の合成と同様の操作により目的錯体を淡茶色
固体として得た。収量194 mg (0.36 mmol, 収率67%)。
In a Schlenk flask, add 220 mg (0.55 mmol) of Mes-imidazole carbene-BEt 3 and 1 Mo (CO) 6
42 mg (0.54 mmol) was weighed and 15 ml of toluene was added. The mixture was heated to reflux for 3 hours. Thereafter, the target complex was obtained as a light brown solid by the same operation as the synthesis of the Mo (CO) 5 ( i Pr-imidazole carbene) complex. Yield 194 mg (0.36 mmol, 67% yield).
1H NMR(in CDCl3) δ 2.08(s,12H,Mes−o−CH3),2.36(s,6H,Mes−p−CH3),7.03(s,4H,Mes−m−H),7.05(s,2H,CH=CH). 13C{1H}NMR(in CDCl3) δ 17.7(Mes−o−CH3),21.2(Mes−p−CH3),123.4(CH=CH),129.3,135.4,137.7,139.5(Mes−Ph),193.2(br, NCN),205.0(cis−CO),211.1(trans−CO). IR(KBr) νCO;1972,1915,1877cm−1. Anal. Calcd for C26H24MoN2O5 C:57.78,H:4.48,N:5.18. Found. C:57.66,H:4.49,N:5.28. 1 H NMR (in CDCl 3 ) δ 2.08 (s, 12H, Mes-o-CH 3 ), 2.36 (s, 6H, Mes-p-CH 3 ), 7.03 (s, 4H, Mes -M-H), 7.05 (s, 2H, CH = CH). 13 C { 1 H} NMR (in CDCl 3 ) δ 17.7 (Mes-o-CH 3 ), 21.2 (Mes-p-CH 3 ), 123.4 (CH═CH), 129.3 135.4, 137.7, 139.5 (Mes-Ph), 193.2 (br, NCN), 205.0 (cis-CO), 211.1 (trans-CO). IR (KBr) νCO; 1972, 1915, 1877 cm −1 . Anal. Calcd for C 26 H 24 MoN 2 O 5 C: 57.78, H: 4.48, N: 5.18. Found. C: 57.66, H: 4.49, N: 5.28.
上記により、Mo(CO)5(Mes-imidazol carbene)錯体の構造決定を行った。 As described above, the structure of the Mo (CO) 5 (Mes-imidazole carbene) complex was determined.
[実施例3]
[Mo(η3-allyl)(amidinato)(CO)2(iPr-imidazol carbene)]錯体の合成
[Example 3]
Synthesis of [Mo (η 3 -allyl) (amidinato) (CO) 2 ( i Pr-imidazol carbene)] complex
まず、[Mo(η3-allyl)Cl(CO)2(pyridine)2]錯体を文献(D. J. Bevan, R. J. Mawby, J
. Chem. Soc., Dalton Trans. (1980) 1904)記載の方法により合成し(前前駆体の合成
)、[Mo(η3-allyl)(amidinato)(CO)2(iPr-imidazol carbene)]錯体の前駆体である [Mo(
η3-allyl)(amidinato)(CO)2(pyridine)]錯体を以下のように合成した。
First, the [Mo (η 3 -allyl) Cl (CO) 2 (pyridine) 2 ] complex was converted from the literature (DJ Bevan, RJ Mawby, J
Chem. Soc., Dalton Trans. (1980) 1904) (pre-precursor synthesis), [Mo (η 3 -allyl) (amidinato) (CO) 2 ( i Pr-imidazole carbene) ] [Mo (
[eta] 3- allyl) (amidinato) (CO) 2 (pyridine)] complex was synthesized as follows.
[Mo(η3-allyl)Cl(CO)2(pyridine)2]錯体(295 mg, 0.76 mmol)のTHF (10ml)溶液を-78℃に冷却した後、ホルムアミジン(N(C6H5)=C(H)N(H)C6H5, 150 mg, 0.67 mmol)とnBuLi (1.50 mol dm-3のヘキサン溶液、0.52 ml, 0.78 mmol)から合成したLi[(PhN)2CH]を加え、撹拌しながら室温まで昇温させた。数時間撹拌した後、減圧下で溶媒を留去し、ヘキサンで数回洗浄した。残査をトルエンで抽出し、減圧下で溶媒を留去することにより、目的錯体である[Mo(η3-allyl)(amidinato)(CO)2(pyridine)]を黄色粉末として得た(325 mg, 0.70 mmol, 収率92%)。この錯体はトルエン/ヘキサンから再結晶することにより、トルエン0.25分子を含む黄色結晶として得ることができた。 After a solution of [Mo (η 3 -allyl) Cl (CO) 2 (pyridine) 2 ] complex (295 mg, 0.76 mmol) in THF (10 ml) was cooled to −78 ° C., formamidine (N (C 6 H 5 ) = C (H) N (H) C 6 H 5 , 150 mg, 0.67 mmol) and n BuLi (1.50 mol dm -3 in hexane, 0.52 ml, 0.78 mmol) and Li [(PhN) 2 CH The mixture was heated to room temperature with stirring. After stirring for several hours, the solvent was distilled off under reduced pressure and washed several times with hexane. The residue was extracted with toluene, and the solvent was distilled off under reduced pressure to obtain the target complex [Mo (η 3 -allyl) (amidinato) (CO) 2 (pyridine)] as a yellow powder (325 mg, 0.70 mmol, 92% yield). This complex could be obtained as yellow crystals containing 0.25 molecules of toluene by recrystallization from toluene / hexane.
IR(KBr): ν(CO)1928,1913,1829cm−1. 1H NMR (toluene−d8,at 30℃): δ 1.46(d,J=9.2Hz,2H,allyl−CH 2),3.52(br,2H,allyl−CH 2),3.70(tt,J=9.6,6.6Hz,1H,allyl−CH),6.14(m,2H,m−C5 H 5N),6.54(m,1H,p−C5 H 5N),7.02(m,10H,C6 H 5),8.26(s,1H,amidinato−CH),8.34(d,J=4.0Hz,2H,o−C5 H 5N). (toluene−d8,at 60℃): δ 1.44(d,J=9.6Hz,2H,allyl−CH 2),3.47(d,J=6.3Hz,2H,allyl−CH 2),3.70(tt,J=9.6,6.6Hz,1H,allyl−CH),6.23(t,J=6.6Hz,2H,m−C5 H 5N),6.64(t,J=7.6Hz,1H,p−C5 H 5N),7.00(m,10H,C6 H 5),8.26(s,1H,amidinato−CH),8.35(d,J=4.9Hz,2H,o−C5 H 5N). (toluene−d8,at −60℃): δ 1.59(d,J=9.9Hz,2H,allyl−CH 2),3.65(tt,J=9.6,6.6Hz,1H,allyl−CH),3.85(d,J=6.6Hz,2H,allyl−CH 2),5.84(t,J=6.9Hz,2H,m−C5 H 5N),6.15(t,J=7.6Hz,1H,p−C5 H 5N),7.07(m,10H,C6 H 5),8.44(s,1H,amidinato−CH),8.45(d,J=5.9Hz,2H,o−C5 H 5N). 13C{1H}NMR (CDCl3,at 55℃): δ 57.7(s,allyl−CH2),75.7(s,allyl−CH),118.2,122.0,129.4,146.8(s,C 6H5),124.5,137.5,151.2(s,C 5H5N),156.2(s,amidinato−CH),227.9(s,CO). Anal. Calcd for C23H21MoN3O2・0.25C7H8: C,60.62;H,4.73;N,8.57. Found:C,60.40;H,5.02;N,8.75. IR (KBr): ν (CO) 1928, 1913, 1829 cm −1 . 1 H NMR (toluene-d 8 , at 30 ° C.): δ 1.46 (d, J = 9.2 Hz, 2H, allyl-C H 2 ), 3.52 (br, 2H, allyl-C H 2 ) , 3.70 (tt, J = 9.6, 6.6 Hz, 1H, allyl-C H ), 6.14 (m, 2H, m-C 5 H 5 N), 6.54 (m, 1H, p-C 5 H 5 N) , 7.02 (m, 10H, C 6 H 5), 8.26 (s, 1H, amidinato-C H), 8.34 (d, J = 4.0Hz, 2H , o-C 5 H 5 N ). (Toluene-d 8 , at 60 ° C.): δ 1.44 (d, J = 9.6 Hz, 2H, allyl-C H 2 ), 3.47 (d, J = 6.3 Hz, 2H, allyl-C H 2), 3.70 (tt, J = 9.6,6.6Hz, 1H, allyl-C H), 6.23 (t, J = 6.6Hz, 2H, m-C 5 H 5 N) , 6.64 (t, J = 7.6Hz , 1H, p-C 5 H 5 N), 7.00 (m, 10H, C 6 H 5), 8.26 (s, 1H, amidinato-C H ), 8.35 (d, J = 4.9 Hz, 2H, o-C 5 H 5 N). (Toluene-d 8 , at −60 ° C.): δ 1.59 (d, J = 9.9 Hz, 2H, allyl-C H 2 ), 3.65 (tt, J = 9.6, 6.6 Hz, 1H, allyl-C H ), 3.85 (d, J = 6.6 Hz, 2H, allyl-C H 2 ), 5.84 (t, J = 6.9 Hz, 2H, m-C 5 H 5 N ), 6.15 (t, J = 7.6 Hz, 1 H, p-C 5 H 5 N), 7.07 (m, 10 H , C 6 H 5 ), 8.44 (s, 1 H, amidinato-C H), 8.45 (d, J = 5.9Hz, 2H, o-C 5 H 5 N). 13 C {1 H} NMR ( CDCl 3, at 55 ℃): δ 57.7 (s, allyl- C H 2), 75.7 (s, allyl- C H), 118.2,122.0, 129.4,146.8 (s, C 6 H 5 ), 124.5,137.5,151.2 (s, C 5 H 5 N), 156.2 (s, amidinato- C H), 227 .9 (s, C 2 O). Anal. Calcd for C 23 H 21 MoN 3 O 2 · 0.25C 7 H 8: C, 60.62; H, 4.73; N, 8.57. Found: C, 60.40; H, 5.02; N, 8.75.
上記により、[Mo(η3-allyl)(amidinato)(CO)2(pyridine)]の構造決定を行った。 As described above, the structure of [Mo (η 3 -allyl) (amidinato) (CO) 2 (pyridine)] was determined.
シュレンクフラスコに上記により得られた[Mo(η3-allyl)(amidinato)(CO)2(pyridine)](57 mg, 0.12 mmol)とiPr-imidazol carbene・BEt3 (38 mg, 0.15 mmol)を計り取り、トルエン(5 ml)を加えて、3時間加熱還流を行った。室温まで放冷した後、減圧下で溶媒を留去し、ヘキサン(3 × 5 ml)で洗浄後、真空乾燥することにより目的錯体である[Mo(η3-allyl)(amidinato)(CO)2(iPr-imidazol carbene)] 錯体を黄色粉末として得た(62 mg, 0.11 mmol, 収率92%)。表題化合物はCH2Cl2から再結晶することにより単結晶を得ることができたので、X線構造解析によりその構造を確認した。 [Mo (η 3 -allyl) (amidinato) (CO) 2 (pyridine)] (57 mg, 0.12 mmol) and i Pr-imidazole carbene · BEt 3 (38 mg, 0.15 mmol) obtained by the above in a Schlenk flask Was measured, toluene (5 ml) was added, and the mixture was heated under reflux for 3 hours. After leaving to cool to room temperature, the solvent was distilled off under reduced pressure, washed with hexane (3 x 5 ml), and then vacuum dried to obtain the target complex [Mo (η 3 -allyl) (amidinato) (CO) 2 ( i Pr-imidazol carbene)] complex was obtained as a yellow powder (62 mg, 0.11 mmol, 92% yield). Since the title compound could be recrystallized from CH 2 Cl 2, a single crystal could be obtained, and its structure was confirmed by X-ray structural analysis.
1H NMR(in CDCl3) δ 0.99(br,12H,iPr−CH3),1.70(d,J=9.9Hz,2H,allyl−CH2),4.09(m,1H,allyl−CH),4.17(d,J=7.3Hz,2H,allyl−CH2),4.58(sept,J=6.6Hz,2H,iPr−CH),6.85〜7.25(m,12H,Ph and HC=CH),8.73(s,1H,amidinato−CH). 13C{1H}NMR(in CDCl3,at 55℃) δ 23.7(iPr−CH3),52.3(iPr−CH),60.6(allyl−CH2),86.1(allyl−CH),117.4(CH=CH),117.8,121.1,129.1,147.4(Ph),153.9(amidinato−NCN),189.4(carbene−NCN),228.6(CO). IR(KBr) νCO;1913,1829cm−1. Anal. Calcd for C27H32MoN4O2. C,60.00;H,5.97;N,10.37. Found. C, 59.68;H,6.12;N,10.01. 1 H NMR (in CDCl 3 ) δ 0.99 (br, 12H, i Pr—CH 3 ), 1.70 (d, J = 9.9 Hz, 2H, allyl-CH 2 ), 4.09 (m, 1H, allyl-CH), 4.17 (d, J = 7.3 Hz, 2H, allyl-CH 2 ), 4.58 (sept, J = 6.6 Hz, 2H, i Pr—CH), 6.85 ˜7.25 (m, 12H, Ph and HC═CH), 8.73 (s, 1H, amidinato-CH). 13 C { 1 H} NMR (in CDCl 3 , at 55 ° C.) δ 23.7 ( i Pr—CH 3 ), 52.3 ( i Pr—CH), 60.6 (allyl-CH 2 ), 86. 1 (allyl-CH), 117.4 (CH = CH), 117.8, 121.1, 129.1, 147.4 (Ph), 153.9 (amidinato-NCN), 189.4 (carbene- NCN), 228.6 (CO). IR (KBr) νCO; 1913, 1829 cm −1 . Anal. Calcd for C 27 H 32 MoN 4 O 2. C, 60.00; H, 5.97; N, 10.37. Found. C, 59.68; H, 6.12; N, 10.1.
上記により、[Mo(η3-allyl)(amidinato)(CO)2(iPr-imidazol carbene)]錯体の構造決
定を行った。
The structure of the [Mo (η 3 -allyl) (amidinato) (CO) 2 ( i Pr-imidazole carbene)] complex was determined as described above.
[実施例4]
[W(η3-allyl)(amidinato)(CO)2(iPr-imidazolcarbene)] 錯体の合成
[Example 4]
Synthesis of [W (η 3 -allyl) (amidinato) (CO) 2 ( i Pr-imidazolcarbene)] complex
まず、[W(η3-allyl)Cl(CO)2(pyridine)2]錯体を文献(D. J. Bevan, R. J. Mawby, J.
Chem. Soc., Dalton Trans. (1980) 1904)記載の方法により合成し(前前駆体の合成)
、[W(η3-allyl)(amidinato)(CO)2(iPr-imidazol carbene)] 錯体の前駆体である [W(η3
-allyl)(amidinato)(CO)2(pyridine)]錯体を以下のように合成した。
[W(η3-allyl)(amidinato)(CO)2(pyridine)]錯体は、[W(η3-allyl)Cl(CO)2(pyridine)2
]錯体(805 mg, 1.70 mmol) と、ホルムアミジン(N(C6H5)=C(H)N(H)C6H5, 335 mg, 1.71 m
mol)とnBuLi (1.30 mol dm-3のヘキサン溶液、1.4 ml, 1.82 mmol)とから合成したLi[(Ph
N)2CH]を用いて、モリブデン錯体の場合と同様の方法により合成した。その結果、目的錯体を黄色粉末として得た(618 mg, 1.11 mmol, 収率65%)。この錯体はトルエン/ヘキサンから再結晶することにより、トルエン0.25分子を含む黄色結晶として得ることができた。
First, the [W (η 3 -allyl) Cl (CO) 2 (pyridine) 2 ] complex is described in the literature (DJ Bevan, RJ Mawby, J.
Chem. Soc., Dalton Trans. (1980) 1904). (Pre-precursor synthesis)
, [W (η 3 -allyl) (amidinato) (CO) 2 ( i Pr-imidazol carbene)] complex precursor [W (η 3
-allyl) (amidinato) (CO) 2 (pyridine)] complex was synthesized as follows.
[W (η 3 -allyl) (amidinato) (CO) 2 (pyridine)] complex is represented by [W (η 3 -allyl) Cl (CO) 2 (pyridine) 2
] Complex (805 mg, 1.70 mmol) and formamidine (N (C 6 H 5 ) = C (H) N (H) C 6 H 5 , 335 mg, 1.71 m
mol) and n BuLi (1.30 mol dm -3 in hexane, 1.4 ml, 1.82 mmol)
N) 2 CH] was synthesized by the same method as in the case of the molybdenum complex. As a result, the target complex was obtained as a yellow powder (618 mg, 1.11 mmol, yield 65%). This complex could be obtained as yellow crystals containing 0.25 molecules of toluene by recrystallization from toluene / hexane.
IR(KBr): ν(CO)1919,1905,1816cm−1. 1H NMR(toluene−d8,at 27℃): δ 1.82(d,J=7.3Hz,2H,allyl−CH 2),2.90(tt,J=9.2,6.6Hz,1H,allyl−CH),3.44(br,2H,allyl−CH 2),6.10(m,2H,m−C5 H 5N),6.50(t,J=7.6Hz,1H,p−C5 H 5N),7.01(m,10H,C6 H 5),8.35(br,2H,o−C5 H 5N),8.89(br,1H,amidinato−CH). (toluene−d8,at 70℃): δ 1.77(d,J=8.9Hz,2H,allyl−CH 2),2.89(tt,J=8.9,6.6Hz,1H,allyl−CH),3.33(d,J=6.3Hz,2H,allyl−CH 2),6.22(t,J=7.3Hz,2H,m−C5 H 5N),6.63(t,J=7.6Hz,1H,p−C5 H 5N),7.00(m,10H,C6 H 5),8.37(d,J=5.3Hz,2H,o−C5 H 5N),8.88(s,1H,amidinato−CH). (toluene−d8,at −45℃): δ 1.99(d,J=9.2Hz,2H,allyl−CH 2),2.88(tt,J=8.9,6.9Hz,1H,allyl−CH),3.74(d,J=6.6Hz,2H,allyl−CH 2),5.85(t,J=7.3Hz,2H,m−C5 H 5N),6.17(t,J=7.9Hz,1H,p−C5 H 5N),7.04(m,10H,C6 H 5),8.42(d,J=5.3Hz,2H,o−C5 H 5N),9.05(s,1H,amidinato−CH). 13C{1H}NMR(C6D6,at 75℃): δ 50.0(s,allyl−CH2),68.6(s,allyl−CH),118.7,122.9,129.7,146.2(s,C 6H5),124.5,137.1,151.0(s,C 5H5N),156.7(s,amidinato−CH),220.9(s,CO). Anal. Calcd for C23H21N3O2W・0.25C7H8: C,51.40;H,4.01;N,7.27. Found: C,51.27;H,4.09;N,7.19. IR (KBr): ν (CO) 1919, 1905, 1816 cm −1 . 1 H NMR (toluene-d 8 , at 27 ° C.): δ 1.82 (d, J = 7.3 Hz, 2H, allyl-C H 2 ), 2.90 (tt, J = 9.2, 6. 6 Hz, 1H, allyl-C H ), 3.44 (br, 2H, allyl-C H 2 ), 6.10 (m, 2H, m-C 5 H 5 N), 6.50 (t, J = 7.6Hz, 1H, p-C 5 H 5 N), 7.01 (m, 10H, C 6 H 5), 8.35 (br, 2H, o-C 5 H 5 N), 8.89 ( br, 1H, amidinato-C H ). (Toluene-d 8 , at 70 ° C.): δ 1.77 (d, J = 8.9 Hz, 2H, allyl-C H 2 ), 2.89 (tt, J = 8.9, 6.6 Hz, 1H) , Allyl-C H ), 3.33 (d, J = 6.3 Hz, 2H, allyl-C H 2 ), 6.22 (t, J = 7.3 Hz, 2H, m-C 5 H 5 N) , 6.63 (t, J = 7.6 Hz, 1H, p-C 5 H 5 N), 7.00 (m, 10H, C 6 H 5 ), 8.37 (d, J = 5.3 Hz, 2H, o-C 5 H 5 N), 8.88 (s, 1H, amidinato-C H). (Toluene-d 8 , at −45 ° C.): δ 1.99 (d, J = 9.2 Hz, 2H, allyl-C H 2 ), 2.88 (tt, J = 8.9, 6.9 Hz, 1H, allyl-C H ), 3.74 (d, J = 6.6 Hz, 2H, allyl-C H 2 ), 5.85 (t, J = 7.3 Hz, 2H, m-C 5 H 5 N ), 6.17 (t, J = 7.9 Hz, 1H, p-C 5 H 5 N), 7.04 (m, 10 H , C 6 H 5 ), 8.42 (d, J = 5.3 Hz) , 2H, o-C 5 H 5 N), 9.05 (s, 1H, amidinato-C H ). 13 C {1 H} NMR ( C 6 D 6, at 75 ℃): δ 50.0 (s, allyl- C H 2), 68.6 (s, allyl- C H), 118.7,122. 9,129.7,146.2 (s, C 6 H 5 ), 124.5,137.1,151.0 (s, C 5 H 5 N), 156.7 (s, amidinato- C H) 220.9 (s, C 2 O). Anal. Calcd for C 23 H 21 N 3 O 2 W · 0.25C 7 H 8: C, 51.40; H, 4.01; N, 7.27. Found: C, 51.27; H, 4.09; N, 7.19.
上記により、[W(η3-allyl)(amidinato)(CO)2(pyridine)]錯体の構造決定を行った。 The structure of the [W (η 3 -allyl) (amidinato) (CO) 2 (pyridine)] complex was determined as described above.
シュレンクフラスコに上記により得られた[W(η3-allyl)(amidinato)(CO)2(pyridine)]
(72 mg, 0.13 mmol)とiPr-imidazol carbene・BEt3 (35 mg, 0.14 mmol)を計り取り、ト
ルエン(10 ml)を加えて、4時間加熱還流を行った。室温まで放冷した後、減圧下で溶媒を留去し、ヘキサン(3 × 5 ml)で洗浄後、真空乾燥することにより目的錯体である[W(η3-allyl)(amidinato)(CO)2(iPr-imidazol carbene)]錯体を黄色粉末として得た(76 mg, 0.12mmol, 収率92 %)。
[W (η 3 -allyl) (amidinato) (CO) 2 (pyridine)] obtained by Schlenk flask as above
(72 mg, 0.13 mmol) and i Pr-imidazole carbene · BEt 3 (35 mg, 0.14 mmol) were weighed, toluene (10 ml) was added, and the mixture was heated to reflux for 4 hours. After allowing to cool to room temperature, the solvent was distilled off under reduced pressure, washed with hexane (3 × 5 ml), and then vacuum dried to obtain the target complex [W (η 3 -allyl) (amidinato) (CO) 2 ( i Pr-imidazol carbene)] complex was obtained as a yellow powder (76 mg, 0.12 mmol, 92% yield).
1H NMR(in CDCl3,at 50℃) δ 0.99(br,12H,iPr−CH3),1.88(d,J=9.9Hz,2H,allyl−CH2),3.18(tt,J=9.9,6.6Hz,1H,allyl−CH),4.13(d,J=6.6Hz,2H,allyl−CH2),4.61(sept,J=6.6Hz,2H,iPr−CH),6.87〜7.25(m,12H,Ph and HC=CH),9.33(s,1H,amidinato−CH).13C{1H}NMR(in CDCl3,at 55℃) δ 23.3(iPr−CH3),52.6(iPr−CH),53.1(allyl−CH2),80.3(allyl−CH),117.4(CH=CH),117.8,121.6,129.1,146.2(Ph),154.3(amidinato−NCN),191.3(carbene−NCN),220.7(CO). IR(KBr) νCO;1904,1818cm−1.Anal. Calcd for C27H32N4O2W. C,51.60;H,5.13;N,8.92. Found. C,51.89;H,4.95;N,9.07. 1 H NMR (in CDCl 3 , at 50 ° C.) δ 0.99 (br, 12H, i Pr—CH 3 ), 1.88 (d, J = 9.9 Hz, 2H, allyl-CH 2 ), 3. 18 (tt, J = 9.9, 6.6 Hz, 1H, allyl-CH), 4.13 (d, J = 6.6 Hz, 2H, allyl-CH 2 ), 4.61 (sept, J = 6 .6 Hz, 2H, i Pr-CH), 6.87-7.25 (m, 12H, Ph and HC = CH), 9.33 (s, 1H, amidinato-CH). 13 C { 1 H} NMR (in CDCl 3 , at 55 ° C.) δ 23.3 ( i Pr—CH 3 ), 52.6 ( i Pr—CH), 53.1 (allyl-CH 2 ), 80. 3 (allyl-CH), 117.4 (CH = CH), 117.8, 121.6, 129.1, 146.2 (Ph), 154.3 (amidinato-NCN), 191.3 (carbene- NCN), 220.7 (CO). IR (KBr) νCO; 1904, 1818 cm −1 . Anal. Calcd for C 27 H 32 N 4 O 2 W. C, 51.60; H, 5.13; N, 8.92. Found. C, 51.89; H, 4.95; N, 9.07.
上記により、[W(η3-allyl)(amidinato)(CO)2(iPr-imidazol carbene)] 錯体の構造決
定を行った。
The structure of the [W (η 3 -allyl) (amidinato) (CO) 2 ( i Pr-imidazole carbene)] complex was determined as described above.
[実施例5]
Mo(CO)4(キシリル架橋二座イミダゾールカルベン)錯体の合成
[Example 5]
Synthesis of Mo (CO) 4 (xylyl bridged bidentate imidazole carbene) complex
シュレンクフラスコにキシリル架橋二座イミダゾールカルベン・(BEt3)2を162 mg (0.3
5 mmol)とMo(CO)6を91 mg (0.34 mmol)を計り取り、真空下-78℃でヘプタンを約10 ml
加えた。室温まで昇温した後、リービッヒ冷却管を取り付け、加熱還流を6時間行った。
反応終了後、室温まで放冷し、無色の上澄み液を除去した後、ヘキサン(3 × 10 ml)で
洗浄後、真空乾燥することにより、目的錯体を黄色粉末として得た。収量138 mg (0.29 m
mol, 収率84%)。
In a Schlenk flask, 162 mg (0.3 t) of xylyl-bridged bidentate imidazole carbene (BEt 3 ) 2 was added.
5 mmol) and 91 mg (0.34 mmol) of Mo (CO) 6 and weigh about 10 ml of heptane at -78 ° C under vacuum.
added. After raising the temperature to room temperature, a Liebig condenser was attached and heated to reflux for 6 hours.
After completion of the reaction, the mixture was allowed to cool to room temperature, the colorless supernatant was removed, washed with hexane (3 × 10 ml), and then vacuum dried to obtain the target complex as a yellow powder. Yield 138 mg (0.29 m
mol, 84% yield).
1H NMR(in CDCl3): δ 4.09(s,6H,NCH3),4.48(d,J=14.5Hz,2H,NCH2Ar),5.72(d,J=14.5Hz,2H,NCH2Ar),6.62(d,J=1.3Hz,2H,HC=CH),6.87(d,J =1.3Hz,2H,HC=CH),7.33(m,4H,Ar−H). (in DMSO−d6): δ 3.96(s,6H,NCH3),4.71(d,J=13.9Hz,2H,NCH2Ar),5.42(d,J=13.9Hz,2H,NCH2Ar),6.90(d,J=1.3Hz,2H,HC=CH),7.29(d,J=1.3Hz,2H,HC=CH),7.34(m,2H,Ar−H),7.48(m,2H,Ar−H). 13C{1H}NMR(in DMSO−d6): δ 51.5(NCH2Ar),120.1,124.1,128.2,131.1,136.3(HC=CH and Ar),191.5(NCN),210.3(CO),218.8(C)
. NCH3のメチル炭素に帰属されるシグナルは溶媒のシグナルと重なっていると思われ確認できなかった。IR(KBr) νCO;1999,1932,1896,1847,1788cm−1. Anal. Calcd for C20H18MoN4O4. C,50.64;H,3.83;N,11.81. Found. C,50.86;H,4.02;N,11.66.
1 H NMR (in CDCl 3 ): δ 4.09 (s, 6H, NCH 3 ), 4.48 (d, J = 14.5 Hz, 2H, NCH 2 Ar), 5.72 (d, J = 14 .5 Hz, 2H, NCH 2 Ar), 6.62 (d, J = 1.3 Hz, 2H, HC = CH), 6.87 (d, J = 1.3 Hz, 2H, HC = CH), 7. 33 (m, 4H, Ar-H). (In DMSO-d 6 ): δ 3.96 (s, 6H, NCH 3 ), 4.71 (d, J = 13.9 Hz, 2H, NCH 2 Ar), 5.42 (d, J = 13. 9 Hz, 2H, NCH 2 Ar), 6.90 (d, J = 1.3 Hz, 2H, HC = CH), 7.29 (d, J = 1.3 Hz, 2H, HC = CH), 7.34 (M, 2H, Ar-H), 7.48 (m, 2H, Ar-H). 13 C { 1 H} NMR (in DMSO-d 6 ): δ 51.5 (NCH 2 Ar), 120.1, 124.1, 128.2, 131.1, 136.3 (HC = CH and Ar ), 191.5 (NCN), 210.3 (CO), 218.8 (C)
. The signal attributed to the methyl carbon of NCH 3 seemed to overlap with the solvent signal and could not be confirmed. IR (KBr) νCO; 1999, 1932, 1896, 1847, 1788 cm −1 . Anal. Calcd for C 20 H 18 MoN 4 O 4. C, 50.64; H, 3.83; N, 11.81. Found. C, 50.86; H, 4.02; N, 11.66.
上記により、Mo(CO)4(キシリル架橋二座イミダゾールカルベン)錯体の構造決定を行っ
た。
The structure of the Mo (CO) 4 (xylyl bridged bidentate imidazole carbene) complex was determined as described above.
[実施例6]
iPr-イミダゾールカルベン・BH3錯体の合成
[Example 6]
i Synthesis of Pr-imidazolecarbene and BH 3 complexes
シュレンクフラスコにiPr-imidazol carbene・BEt3を155 mg (0.62 mmol)を計り取り、
真空下-78℃でTHFを約10 ml 加えた。室温まで昇温させた後、 BH3・THF錯体(1.07 M
THF溶液)を0.60 ml (0.64 mmol)を加え、室温で1時間撹拌した。反応溶液は淡黄色から無色透明に変化した。その後、減圧下で溶媒を留去し、ペンタンで洗浄することにより目的化合物を白色固体として得た。収量32 mg (0.19 mmol, 収率31%)。反応は定量的に進行するが、生成物がペンタンに可溶であるため収率が低下した。
In a Schlenk flask, weigh 155 mg (0.62 mmol) of i Pr-imidazole carbene · BEt 3 ,
About 10 ml of THF was added at -78 ° C under vacuum. After heating to room temperature, BH 3 • THF complex (1.07 M
0.60 ml (0.64 mmol) of THF solution was added, and the mixture was stirred at room temperature for 1 hour. The reaction solution changed from pale yellow to colorless and transparent. Then, the solvent was distilled off under reduced pressure, and the target compound was obtained as a white solid by washing with pentane. Yield 32 mg (0.19 mmol, 31% yield). Although the reaction progressed quantitatively, the yield decreased because the product was soluble in pentane.
1H NMR(in C6D6) δ 0.93(d,J=7.3Hz,12H,iPr−CH3),2.11(q,J=87.7Hz,3H,BH3) 5.26(sept,J =6.6Hz,2H,iPr−CH),6.17(s,2H,CH=CH). 13C{1H}NMR(in C6D6) δ 22.2(iPr−CH3),49.1(iPr−CH),114.5(CH=CH). カルベン炭素に帰属されるシグナルは確認できなかった。11B NMR (in C6D6) δ −36.4(q,J=88.0Hz,BH3).IR (KBr): 3125,2979,2386,2291,2224,1442,1227,1213. Anal. Calcd for C9H19BN2:C,65.09;H,11.53;N,16.87. Found: C,64.86;H,11.94;N,16.59. 1 H NMR (in C 6 D 6 ) δ 0.93 (d, J = 7.3 Hz, 12H, i Pr—CH 3 ), 2.11 (q, J = 87.7 Hz, 3H, BH 3 ) 5 .26 (sept, J = 6.6 Hz, 2H, i Pr-CH), 6.17 (s, 2H, CH = CH). 13 C { 1 H} NMR (in C 6 D 6 ) δ 22.2 ( i Pr—CH 3 ), 49.1 ( i Pr—CH), 114.5 (CH═CH). A signal attributed to the carbene carbon could not be confirmed. 11 B NMR (in C 6 D 6 ) δ-36.4 (q, J = 88.0 Hz, BH 3 ). IR (KBr): 3125, 2979, 2386, 2291, 2224, 1442, 1227, 1213. Anal. Calcd for C 9 H 19 BN 2 : C, 65.09; H, 11.53; N, 16.87. Found: C, 64.86; H, 11.94; N, 16.59.
上記により、iPr-イミダゾールカルベン・BH3錯体の構造決定を行った。 As described above, the structure of the i Pr-imidazole carbene / BH 3 complex was determined.
[実施例7]
Mes-イミダゾールカルベン・BH3錯体の合成
[Example 7]
Synthesis of Mes-imidazole carbene and BH 3 complex
Mes-imidazol carbene・BEt3 76 mg (0.19 mmol)とBH3・THF錯体 0.18 ml (0.19 mmol)
とを、THF (約10 ml)中、室温で1時間撹拌した。その後、iPr-イミダゾールカルベン・BH
3付加体の合成と同様の操作により、目的化合物を白色固体として単離した。収量73 mg(0
.18 mmol, 収率93%)。
Mes-imidazole carbene ・ BEt 3 76 mg (0.19 mmol) and BH 3・ THF complex 0.18 ml (0.19 mmol)
Were stirred in THF (ca. 10 ml) for 1 h at room temperature. Then i Pr-Imidazolecarbene / BH
The target compound was isolated as a white solid by the same operation as in the synthesis of the 3- adduct. Yield 73 mg (0
.18 mmol, 93% yield).
1H NMR(in C6D6) δ 2.05(s,12H,Mes−o−CH3),2.09(s,6H,Mes−p−CH3),5.99(s,2H,CH=CH),6.74(s,4H,Mes−m−H). BH3に帰属されるシグナルは観測できなかった。11B NMR(in C6D6) δ −36.8(q,J=88.0Hz,BH3). 1 H NMR (in C 6 D 6) δ 2.05 (s, 12H, Mes-o-CH 3), 2.09 (s, 6H, Mes-p-CH 3), 5.99 (s, 2H , CH = CH), 6.74 (s, 4H, Mes-m-H). No signal attributed to BH 3 could be observed. 11 B NMR (in C 6 D 6 ) δ-36.8 (q, J = 88.0 Hz, BH 3 ).
上記により、Mes-イミダゾールカルベン・BH3錯体の構造決定を行った。 The structure of the Mes-imidazole carbene / BH 3 complex was determined as described above.
本化合物は文献既知化合物である。T. Ramnial, H. Jong, I. D. McKenzie, M. Jennin
gs, J. A. C. Clyburne, Chem. Commun., 2003, 1722.
This compound is a known compound in the literature. T. Ramnial, H. Jong, ID McKenzie, M. Jennin
gs, JAC Clyburne, Chem. Commun., 2003, 1722.
考察
以上の実施例から明らかなように、本発明の製造法によるとKOtBu等の塩基を使用せず
にかつ温和な条件下でカルベン錯体を合成できることが分かった。
DISCUSSION As is clear from the above examples, it has been found that according to the production method of the present invention, a carbene complex can be synthesized without using a base such as KO t Bu and under mild conditions.
Claims (2)
R2は1から50個の炭素原子を有するアルキル基、1から50個の炭素原子を有するアルケニル基、1から50個の炭素原子を有するアルキニル基、および1から30個の炭素原子を有するアリール基よりなる群から選択され、これらの置換基は環式、非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換されていてもよい。
R3およびR4は、同一または異なり、それぞれ水素、ハロゲン、ニトロ基、ニトロソ基、アルコキシル基、アリールオキシ基、アミド基、カルボキシル基、カルボニル基、チオ基、スルホニル基、1から50個の炭素原子を有するアルキル基、1から50個の炭素原子を有するアルケニル基、1から50個の炭素原子を有するアルキニル基、および1から30個の炭素原子を有するアリール基よりなる群から選択され、これらの置換基は環式、非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換されていてもよい。
Eは13族の元素であり、R5 は、炭素数1から20個のアルキル基、アリール基、アルコキシル基からなる群から選択され、さらにこれらのうち少なくとも1つの水素はアルコキシル基に置換されていてもよく、n’は1から4の整数である。]
一般式(2)で示される金属錯体とを用いることを特徴とする、
一般式(3)で示されるイミダゾールカルベン金属錯体の製造方法。
R2は1から50個の炭素原子を有するアルキル基、1から50個の炭素原子を有するアルケニル基、1から50個の炭素原子を有するアルキニル基、および1から30個の炭素原子を有するアリール基よりなる群から選択され、これらの置換基は環式、非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換されていてもよい。
R3およびR4は、同一または異なり、それぞれ水素、ハロゲン、ニトロ基、ニトロソ基、アルコキシル基、アリールオキシ基、アミド基、カルボキシル基、カルボニル基、チオ基、スルホニル基、1から50個の炭素原子を有するアルキル基、1から50個の炭素原子を有するアルケニル基、1から50個の炭素原子を有するアルキニル基、および1から30個の炭素原子を有するアリール基よりなる群から選択され、これらの置換基は環式、非環式、直鎖および/または分枝鎖の基を含んでもよく、少なくとも1個の水素は官能基で交換されていてもよい。
Mは6から10族の遷移金属元素で、低原子価(0から3価)の遷移金属元素であり、Lは中心金属に配位した単座または多座の荷電または荷電していない複数個の配位子である。] An imidazole carbene adduct represented by the general formula (1);
R 2 is an alkyl group having 1 to 50 carbon atoms, an alkenyl group having 1 to 50 carbon atoms, an alkynyl group having 1 to 50 carbon atoms, and an aryl having 1 to 30 carbon atoms Selected from the group consisting of groups, these substituents may include cyclic, acyclic, linear and / or branched groups and at least one hydrogen may be replaced with a functional group .
R 3 and R 4 are the same or different and are each hydrogen, halogen, nitro group, nitroso group, alkoxyl group, aryloxy group, amide group, carboxyl group, carbonyl group, thio group, sulfonyl group, 1 to 50 carbons Selected from the group consisting of alkyl groups having atoms, alkenyl groups having 1 to 50 carbon atoms, alkynyl groups having 1 to 50 carbon atoms, and aryl groups having 1 to 30 carbon atoms, and The substituents may include cyclic, acyclic, straight chain and / or branched groups, and at least one hydrogen may be replaced with a functional group.
E is a Group 13 element, R 5 is selected from the group consisting of an alkyl group having 1 to 20 carbon atoms, an aryl group, and an alkoxyl group, and at least one of these hydrogens is substituted with an alkoxyl group. N ′ is an integer from 1 to 4. ]
Using a metal complex represented by the general formula (2),
The manufacturing method of the imidazole carbene metal complex shown by General formula (3).
R 2 is an alkyl group having 1 to 50 carbon atoms, an alkenyl group having 1 to 50 carbon atoms, an alkynyl group having 1 to 50 carbon atoms, and an aryl having 1 to 30 carbon atoms Selected from the group consisting of groups, these substituents may include cyclic, acyclic, linear and / or branched groups and at least one hydrogen may be replaced with a functional group .
R 3 and R 4 are the same or different and are each hydrogen, halogen, nitro group, nitroso group, alkoxyl group, aryloxy group, amide group, carboxyl group, carbonyl group, thio group, sulfonyl group, 1 to 50 carbons Selected from the group consisting of alkyl groups having atoms, alkenyl groups having 1 to 50 carbon atoms, alkynyl groups having 1 to 50 carbon atoms, and aryl groups having 1 to 30 carbon atoms, and The substituents may include cyclic, acyclic, straight chain and / or branched groups, and at least one hydrogen may be replaced with a functional group.
M is a transition metal element of group 6 to 10 and is a low valence (0 to 3 valence) transition metal element, and L is a monodentate or multidentate charged or uncharged plural coordinated to the central metal. It is a ligand. ]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004049441A JP4680519B2 (en) | 2004-02-25 | 2004-02-25 | Method for producing imidazole carbene metal complex |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004049441A JP4680519B2 (en) | 2004-02-25 | 2004-02-25 | Method for producing imidazole carbene metal complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005239607A JP2005239607A (en) | 2005-09-08 |
| JP4680519B2 true JP4680519B2 (en) | 2011-05-11 |
Family
ID=35021722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004049441A Expired - Fee Related JP4680519B2 (en) | 2004-02-25 | 2004-02-25 | Method for producing imidazole carbene metal complex |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4680519B2 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19610908A1 (en) * | 1996-03-20 | 1997-09-25 | Hoechst Ag | Process for the production of heterocyclic carbenes |
| JP2001122885A (en) * | 1999-10-28 | 2001-05-08 | Nippon Zeon Co Ltd | Ruthenium complex, method for producing the same, polymerization catalyst and method for producing cyclic olefin polymer |
-
2004
- 2004-02-25 JP JP2004049441A patent/JP4680519B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005239607A (en) | 2005-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tarrieu et al. | Readily accessible unsymmetrical unsaturated 2, 6-diisopropylphenyl N-heterocyclic carbene ligands. Applications in enantioselective catalysis | |
| Zhu et al. | Lanthanide amido complexes incorporating amino-coordinate-lithium bridged bis (indolyl) ligands: synthesis, characterization, and catalysis for hydrophosphonylation of aldehydes and aldimines | |
| Kopf et al. | Ruthenium carbene, vinylidene, and allenylidene complexes with a bis (3, 5-dimethylpyrazol-1-yl) acetato heteroscorpionate ligand | |
| Mashima et al. | Convenient synthesis of anionic dinuclear ruthenium (II) complexes [NR2H2][{RuCl (diphosphine)} 2 (μ-Cl) 3][diphosphine= 2, 2′-bis (diphenylphosphino)-1, 1′-binaphthyl, 2, 2′-bis (di (p-tolyl) phosphino)-1, 1′-binaphthyl, and 1, 2-bis (diphenylphosphino) benzene]: crystal structure of [NEt2H2][{RuCl (1, 2-bis (diphenylphosphino) benzene)} 2 (μ-Cl) 3] | |
| Kanyiva et al. | Practical approach for hydroheteroarylation of alkynes using bench-stable catalyst | |
| EP0582668A1 (en) | Chiral tridentate bis(phospholane) ligands | |
| US7754902B2 (en) | Ruthenium(II) catalysts for use in stereoselective cyclopropanations | |
| MXPA04002943A (en) | Novel disphospines, their complexes with transition metals and their use in asymmetric synthesis. | |
| Schouteeten et al. | A robust dimethylgold (III) complex stabilized by a 2-pyridyl-2-pyrrolide ligand | |
| Li et al. | Synthesis, characterization of bridged bis (amidinate) lanthanide amides and their application as catalysts for addition of amines to nitriles for monosubstituted N-arylamidines | |
| Demir et al. | Synthesis and catalytic properties of novel ruthenium N-heterocyclic-carbene complexes | |
| Cramer et al. | Crystal and molecular structure of a biscyclopentadienyluranium (IV) phosphoylide dimer,[. mu.-(CH)(CH2) P (C6H5) 2U (C5H5) 2] 2.(C2H5) 2O | |
| Yang et al. | Catalytic activity of chelating N-heterocyclic carbene palladium complexes towards selective phosphorylation of coumarins | |
| JP2015024976A (en) | Method for producing optically active secondary alcohol | |
| Zheng et al. | Synthesis of new dipyridinylamine and dipyridinylmethane ligands and their coordination chemistry with Mg (II) and Zn (II) | |
| JP4680519B2 (en) | Method for producing imidazole carbene metal complex | |
| JP2010030992A (en) | Method for producing optically active amine compound | |
| Armstrong et al. | Syntheses and structures of an unsolvated tetrakisimidophosphate {Li 3 [P (NBu t) 3 (NSiMe 3)]} 2 and the face-sharing double-cubane {Li 2 (THF)[P (O)(NBu t) 2 (NHBu t)]} 2 | |
| Brugat et al. | Synthesis and characterization of a new chiral phosphinothiol ligand and its palladium (II) complexes | |
| Hoerlin et al. | Reactions of (isocyanide) cobalt complexes with azides: a template synthesis of carbodiimides on a transition-metal center | |
| Yao et al. | Palladacyclo-promoted asymmetric hydrophosphination reaction between diphenylphosphine and 2-ethynylpyridine | |
| JP2019127484A (en) | Vanadium complex and nitrogen fixation method using the same | |
| Chang et al. | Reactions of ruthenium cyclopropenyl complexes containing pentamethylcyclopentadienyl ligands | |
| Klahn et al. | Menthyl-substituted group 4 metallocene dihalides | |
| Shishkov et al. | Reversible substrate binding at copper centers in neutral copper (I) carbene complexes derived from bis (3-tert-butylimidazole-2-ylidene) methane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101026 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110125 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110203 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4680519 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140210 Year of fee payment: 3 |
|
| RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20120319 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A072 Effective date: 20120807 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140210 Year of fee payment: 3 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D07 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |